These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29436696)

  • 21. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
    Daniel SK; Seo YD; Pillarisetty VG
    Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
    Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
    Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.
    Matsusue R; Kubo H; Hisamori S; Okoshi K; Takagi H; Hida K; Nakano K; Itami A; Kawada K; Nagayama S; Sakai Y
    Ann Surg Oncol; 2009 Sep; 16(9):2645-53. PubMed ID: 19588204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
    Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
    Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis：A study in vitro and in vivo.
    Qin L; Qin J; Zhen X; Yang Q; Huang L
    Biomed Pharmacother; 2018 May; 101():599-607. PubMed ID: 29518606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
    Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
    Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
    Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
    J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
    BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
    Chen L; Chen Q; Wu Y; Zhu M; Hu J; Zhuang Z
    Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33649808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer-Associated-Fibroblast-Mediated Paracrine and Autocrine SDF-1/CXCR4 Signaling Promotes Stemness and Aggressiveness of Colorectal Cancers.
    Chen CY; Yang SH; Chang PY; Chen SF; Nieh S; Huang WY; Lin YC; Lee OK
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CXCR4/CXCL12 axis via [
    Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2744-2757. PubMed ID: 38587644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway.
    Saiman Y; Agarwal R; Hickman DA; Fausther M; El-Shamy A; Dranoff JA; Friedman SL; Bansal MB
    Am J Physiol Gastrointest Liver Physiol; 2013 Sep; 305(5):G375-82. PubMed ID: 23812037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer.
    Wang X; Cao Y; Zhang S; Chen Z; Fan L; Shen X; Zhou S; Chen D
    Oncotarget; 2017 May; 8(22):36149-36160. PubMed ID: 28193907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
    Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
    Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.